{"id":"velcade-administered-by-subcutaneous-injection","safety":{"commonSideEffects":[{"rate":"40-50%","effect":"Neutropenia"},{"rate":"30-40%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Pyrexia"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"VELCADE works by binding to the proteasome, a complex of proteins that breaks down damaged or unneeded proteins in cells. By inhibiting the proteasome, VELCADE prevents the breakdown of proteins that are involved in cell growth and survival, ultimately leading to cell death.","oneSentence":"VELCADE is a proteasome inhibitor that blocks the action of proteasomes in cells, leading to cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:26.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT05083169","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-14","conditions":"Multiple Myeloma","enrollment":587},{"nctId":"NCT04151667","phase":"PHASE2","title":"Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-22","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT03652064","phase":"PHASE3","title":"A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-06","conditions":"Multiple Myeloma","enrollment":395},{"nctId":"NCT05695508","phase":"PHASE2","title":"GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5","status":"RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2022-12-01","conditions":"Multiple Myeloma","enrollment":160},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT03201965","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-05","conditions":"Amyloidosis","enrollment":416},{"nctId":"NCT02195479","phase":"PHASE3","title":"A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-09","conditions":"Multiple Myeloma","enrollment":706},{"nctId":"NCT06497738","phase":"","title":"A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-05-01","conditions":"Multiple Myeloma","enrollment":112},{"nctId":"NCT03314181","phase":"PHASE2","title":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-04-02","conditions":"Multiple Myeloma","enrollment":156},{"nctId":"NCT07045909","phase":"PHASE2","title":"Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)","status":"RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2025-06-30","conditions":"De Novo Multiple Myeloma, Anitocabtagene Autoleucel","enrollment":30},{"nctId":"NCT04052880","phase":"PHASE2","title":"Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Larysa Sanchez","startDate":"2019-10-24","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":17},{"nctId":"NCT03412565","phase":"PHASE2","title":"A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-26","conditions":"Multiple Myeloma","enrollment":265},{"nctId":"NCT04166565","phase":"PHASE2","title":"Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-10-31","conditions":"Multiple Myeloma, Extramedullary Plasmacytoma","enrollment":41},{"nctId":"NCT05849610","phase":"PHASE2","title":"Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2023-09-21","conditions":"High-Risk de Novo Multiple Myeloma","enrollment":30},{"nctId":"NCT06418477","phase":"PHASE2","title":"Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-06-15","conditions":"Monoclonal Gammopathy of Renal Significance","enrollment":20},{"nctId":"NCT02375555","phase":"PHASE2","title":"Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-05-07","conditions":"Multiple Myeloma","enrollment":40},{"nctId":"NCT03000634","phase":"PHASE2","title":"2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2017-04-01","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT05889221","phase":"NA","title":"Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2023-10-23","conditions":"Multiple Myeloma, Myeloma Multiple, Myeloma","enrollment":74},{"nctId":"NCT06189833","phase":"PHASE2","title":"Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS","status":"RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-11-23","conditions":"Multiple Myeloma","enrollment":200},{"nctId":"NCT02352558","phase":"PHASE1","title":"A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2015-05","conditions":"Hematologic Malignancy","enrollment":15},{"nctId":"NCT02755597","phase":"PHASE3","title":"A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-07-11","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":291},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241},{"nctId":"NCT01833143","phase":"PHASE2","title":"Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-04-11","conditions":"Non-Small Cell Lung Cancer","enrollment":17},{"nctId":"NCT01383759","phase":"NA","title":"Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-06-24","conditions":"Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD)","enrollment":20},{"nctId":"NCT03044353","phase":"PHASE2","title":"Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-07-10","conditions":"Amyloidosis","enrollment":7},{"nctId":"NCT01818752","phase":"PHASE3","title":"Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-07-08","conditions":"Multiple Myeloma","enrollment":955},{"nctId":"NCT03168100","phase":"PHASE2","title":"2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"University of Arkansas","startDate":"2017-10-01","conditions":"Multiple Myeloma","enrollment":""},{"nctId":"NCT02254551","phase":"PHASE2","title":"Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2015-01","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT00671112","phase":"PHASE1","title":"Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma","status":"TERMINATED","sponsor":"Brian Hill, MD, PhD","startDate":"2008-06","conditions":"714leukemia, Lymphoma","enrollment":30},{"nctId":"NCT00722566","phase":"PHASE3","title":"A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":222}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"VELCADE Administered by subcutaneous injection","genericName":"VELCADE Administered by subcutaneous injection","companyName":"Millennium Pharmaceuticals, Inc.","companyId":"millennium-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VELCADE is a proteasome inhibitor that blocks the action of proteasomes in cells, leading to cell death. Used for Multiple myeloma, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}